| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sunmee Wee, Zhixia Wang, William L Woolverton, Luigi Pulvirenti, George F Koo. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17327886. |
aripiprazole is a dopamine (da) d(2) receptor partial agonist, approved by the food and drug administration (fda) for the treatment of schizophrenia. |
2007-11-20 |
2023-08-12 |
rat |
| Gilbert J L'Italien, Daniel E Casey, Hong J Kan, William H Carson, Ronald N Marcu. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. The Journal of clinical psychiatry. vol 68. issue 10. 2007-11-19. PMID:17960964. |
comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. |
2007-11-19 |
2023-08-12 |
Not clear |
| Gilbert J L'Italien, Daniel E Casey, Hong J Kan, William H Carson, Ronald N Marcu. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. The Journal of clinical psychiatry. vol 68. issue 10. 2007-11-19. PMID:17960964. |
we compared both the rate and incidence of metabolic syndrome among schizophrenia patients (dsm-iv criteria) treated with the atypical antipsychotics aripiprazole or olanzapine or placebo from 4 double-blind, randomized, controlled clinical trials. |
2007-11-19 |
2023-08-12 |
Not clear |
| Jessica W Lea, Steven C Stoner, Jeremy Lafollett. Agitation associated with aripiprazole initiation. Pharmacotherapy. vol 27. issue 9. 2007-11-06. PMID:17723088. |
we describe three patients with long histories of treatment for schizophrenia or schizoaffective disorder in whom conversion to aripiprazole was being attempted. |
2007-11-06 |
2023-08-12 |
Not clear |
| John M Kane, David T Crandall, Ronald N Marcus, James Eudicone, Andrei Pikalov, William H Carson, Wim Swyze. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophrenia research. vol 95. issue 1-3. 2007-10-24. PMID:17644313. |
symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. |
2007-10-24 |
2023-08-12 |
Not clear |
| John M Kane, David T Crandall, Ronald N Marcus, James Eudicone, Andrei Pikalov, William H Carson, Wim Swyze. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophrenia research. vol 95. issue 1-3. 2007-10-24. PMID:17644313. |
this analysis examined symptomatic remission in acutely ill patients with schizophrenia receiving either aripiprazole or haloperidol for one year. |
2007-10-24 |
2023-08-12 |
Not clear |
| Joo-Cheol Shim, Jae-Goo K Shin, Deanna L Kelly, Do-Un Jung, Young-Soo Seo, Kwang-Hyeon Liu, Ji-Hong Shon, Robert R Conle. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. The American journal of psychiatry. vol 164. issue 9. 2007-10-09. PMID:17728426. |
the authors investigated the effect of adjunctive treatment with aripiprazole on hyperprolactinemia and psychopathology in patients with schizophrenia maintained with haloperidol. |
2007-10-09 |
2023-08-12 |
Not clear |
| David Mamo, Ariel Graff, Romina Mizrahi, C M Shammi, Françoise Romeyer, Shitij Kapu. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. The American journal of psychiatry. vol 164. issue 9. 2007-10-09. PMID:17728427. |
differential effects of aripiprazole on d(2), 5-ht(2), and 5-ht(1a) receptor occupancy in patients with schizophrenia: a triple tracer pet study. |
2007-10-09 |
2023-08-12 |
Not clear |
| David Mamo, Ariel Graff, Romina Mizrahi, C M Shammi, Françoise Romeyer, Shitij Kapu. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. The American journal of psychiatry. vol 164. issue 9. 2007-10-09. PMID:17728427. |
the authors conducted a positron emission tomography (pet) study to characterize the simultaneous effects of aripiprazole at the d(2), 5-ht(2), and 5-ht(1a) receptors in patients with schizophrenia or schizoaffective disorder. |
2007-10-09 |
2023-08-12 |
Not clear |
| Gary Sullivan, Markus Bienroth, Martin Jones, Helen Millar, Lawrence Ratna, David Taylo. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Current medical research and opinion. vol 23. issue 7. 2007-09-18. PMID:17588303. |
practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a uk multidisciplinary panel. |
2007-09-18 |
2023-08-12 |
Not clear |
| Gary Sullivan, Markus Bienroth, Martin Jones, Helen Millar, Lawrence Ratna, David Taylo. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Current medical research and opinion. vol 23. issue 7. 2007-09-18. PMID:17588303. |
in accordance with the uk nice guidance on the use of antipsychotic treatment for schizophrenia (2002), aripiprazole may be an appropriate therapeutic option for patients with schizophrenia who are newly diagnosed, in acute relapse or experiencing tolerability problems, adverse metabolic effects or dissatisfaction with their current medication. |
2007-09-18 |
2023-08-12 |
Not clear |
| D Levoyer, D Drapier, G Fadier-Salicé, B Mille. [Clinical impact of aripiprazole in patients suffering from schizophrenia]. L'Encephale. vol 33. issue 3 Pt 1. 2007-09-06. PMID:17675931. |
[clinical impact of aripiprazole in patients suffering from schizophrenia]. |
2007-09-06 |
2023-08-12 |
Not clear |
| D Levoyer, D Drapier, G Fadier-Salicé, B Mille. [Clinical impact of aripiprazole in patients suffering from schizophrenia]. L'Encephale. vol 33. issue 3 Pt 1. 2007-09-06. PMID:17675931. |
in this study, we present seven case reports concerning patients suffering from schizophrenia or schizo-affective disorders, treated by aripiprazole. |
2007-09-06 |
2023-08-12 |
Not clear |
| Divya Vohor. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Current opinion in investigational drugs (London, England : 2000). vol 8. issue 7. 2007-09-04. PMID:17659473. |
this review focuses on the comparative safety and efficacy profile of nine atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine), which may ultimately affect the therapeutic options available for patients with schizophrenia. |
2007-09-04 |
2023-08-12 |
Not clear |
| Sun H Kim, Oxana Ivanova, Fahim A Abbasi, Cindy A Lamendola, Gerald M Reaven, Ira D Glic. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Journal of clinical psychopharmacology. vol 27. issue 4. 2007-08-28. PMID:17632220. |
in an open-label pilot study, we evaluated the metabolic and psychiatric efficacy of switching to aripiprazole in 15 (9 men, 6 women) outpatients with schizophrenia who had gained at least 10 kg on their previous antipsychotic regimen. |
2007-08-28 |
2023-08-12 |
Not clear |
| Sun H Kim, Oxana Ivanova, Fahim A Abbasi, Cindy A Lamendola, Gerald M Reaven, Ira D Glic. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Journal of clinical psychopharmacology. vol 27. issue 4. 2007-08-28. PMID:17632220. |
in conclusion, switching to aripiprazole alone does not ameliorate the highly prevalent metabolic abnormalities in the schizophrenia population who have gained weight on other second generation antipsychotic medications. |
2007-08-28 |
2023-08-12 |
Not clear |
| David Taylo. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-based mental health. vol 10. issue 3. 2007-08-22. PMID:17652558. |
haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. |
2007-08-22 |
2023-08-12 |
Not clear |
| Marc De Hert, Linda Hanssens, Ruud van Winkel, Martien Wampers, Dominique Van Eyck, Andre Scheen, Joseph Peusken. A case series: evaluation of the metabolic safety of aripiprazole. Schizophrenia bulletin. vol 33. issue 3. 2007-08-17. PMID:16940338. |
thirty-one consecutive patients with schizophrenia who were started on aripiprazole were included in the study. |
2007-08-17 |
2023-08-12 |
Not clear |
| Antonio Pret. New developments in the pharmacotherapy of cocaine abuse. Addiction biology. vol 12. issue 2. 2007-08-17. PMID:17508985. |
on the basis of the known neurochemistry of cocaine, some target compounds have been studied: among others, bp-897, a d3 partial agonist; vanoxerine, a highly selective inhibitor of dopamine uptake; aripiprazole, a partial mixed-action agonist approved for the treatment of schizophrenia. |
2007-08-17 |
2023-08-12 |
Not clear |
| Martyn Wood, Charlie Reavil. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert opinion on investigational drugs. vol 16. issue 6. 2007-07-20. PMID:17501690. |
aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. |
2007-07-20 |
2023-08-12 |
Not clear |